Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tianjin Jinster Vaccine
Tianjin, Tianjin, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Tianjin Jinster Vaccine is a Chinese biotechnology company specializing in the research, development, and manufacturing of innovative vaccine products. The company focuses on high-value vaccine candidates, including recombinant human papillomavirus (HPV) vaccines and COVID-19 vaccines. Leveraging its recombinant protein technology platform, Jinster aims to address significant public health challenges through the production of safe and effective immunotherapies. The company is part of the growing biotech cluster in Tianjin, contributing to China's domestic vaccine self-sufficiency and global health initiatives.
- Therapeutic areas
- Infectious DiseasesOncology
- Modalities
- VaccineBiologicRecombinant protein
- Industry
- Biotech
Beyond the preview
Go deeper on Tianjin Jinster Vaccine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tianjin Jinster Vaccine.